AI Bioprocess Modeling Startup Gets Funding

- BioReact's platform is designed to unify offline and online bioprocess data, using AI to model variables like media composition and pH to simulate up to 10,000 experiments in a single optimization run. The company's co-founders are Mitchell Castetter, a former biotech sales executive, and Joanna Lipinski, PhD, a veteran in software and bioinformatics. - The AI models function as a digital twin, creating a dynamic virtual simulation of the physical bioreactor. This allows for in-silico process changes and scenario testing to determine corrective actions, which is critical in regulated GMP environments to ensure data integrity and traceability. - A primary challenge in viral vector manufacturing that AI can address is scalability; traditional adherent cell culture methods are labor-intensive and difficult to scale up from small lab batches. AI-driven platforms can help optimize the transition to more scalable suspension-based cultures by modeling and predicting performance at larger volumes. - The underlying technology addresses common biomanufacturing data challenges, including siloed data streams from bioreactor logs and offline assays, which often lead to redundant experiments. By integrating these disparate datasets, the system aims to shorten the Design-Build-Test-Learn (DBTL) loop from months to weeks. - Hurricane Ventures, launched in April 2023, is a venture capital fund managed by FortySix Venture Capital in partnership with the University of Tulsa, focusing on pre-seed to Series A investments in technology companies connected to the university. BioReact is the 12th company to receive investment from the fund. - The broader biotech venture funding climate has seen a rebound in 2024 and Q1 2025 after a downturn, with investors showing renewed confidence, particularly in companies utilizing AI. However, the trend favors fewer, larger deals in later-stage, de-risked companies with strong clinical data.